Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelotanserin Open-label Extension in LBD
NCT02871427Phase 2Terminated
- Sponsor
- Sio Gene Therapies
- Start
- Oct 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelotanserin in Lewy body dementia (LBD), Visual hallucination (VH) and REM sleep behavior disorder (RBD), sponsored by Sio Gene Therapies. Primary endpoints: Long-term safety and tolerability at 24 weeks and Long-term effectiveness at 24 weeks. Started Oct 2016; status: terminated.
02
Drugs
nelotanserin
03
Conditions
Lewy body dementia (LBD)Visual hallucination (VH)REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT02871427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871427.